To determine the potential of STK24 inhibition as a strategy for overcoming tumor immune evasion in vivo, we investigated the delivery of exogenous Stk24 siRNA into tumor tissues to enhance the immunotherapeutic effect. This evidence concerns the gene STK24 and neoplasm.